Description: MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Home Page: www.medincell.com
3 rue des FrEres LumiEre
Jacou,
34830
France
Phone:
33 4 67 02 13 67
Officers
| Name | Title |
|---|---|
| Mr. Christophe Douat | Chief Executive Officer & Director |
| Mr. Franck Pouzache | Chief People Officer & Member of the Management Board |
| Mr. Stephane Postic | Chief Financial Officer |
| Julie Alimi | Head of Legal |
| Mr. David Heuze | Head of Communications |
| Mr. Adolfo Lopez-Noriega | Head of Research & Development |
| Mr. Sebastien Enault | Chief Business Officer |
| Ms. Helen Martin | Head of Alliance & Project Management |
| Ms. Quiterie De Beauregard | Head of Global Health Development |
| Dr. Richard Malamut M.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 27.4772 |
| Price-to-Sales TTM: | 40.72 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 134 |